FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* ROSENWALD LINDSAY A MD				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 2 GANSEVOORT STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/05/2020									er (give title belo		Other (specify	pelow)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
NEW YO	ORK, NY	10014											ed by whole than	One Reporting	i cison	
(City	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execu	2A. Deemed Execution Date, if any (Month/Day/Year	if C	Transac ode nstr. 8)	(A) or Disposed of		of (D)	(D) Beneficially Ov Reported Trans		ollowing	Ownership Form:	Beneficial	
				(Mon		ar)	Code	V	Amoun	(A) or t (D)	Price	(Instr. 3 a	nd 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
СОММО	ON STOCE	K	06/05/2020				A		24,390 (1)) A	\$ 0	262,280) (2)		D	
			Table II - I				t Acquire	he fo	orm dis	plays a of	curre eficial	ntly valid	uired to res			
1 Tid C	l ₂	2 T	1	0 / 1	ıts, calls, v						T	:41	0 D.:f	0. M	- C 10	11 Notes
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	Execution Day (ear) any	te, if Transaction Code (Instr. 8)		of Der Sec Acq (A)	ivative urities uired	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Und Secu	itle and ount of lerlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficia Ownershi (Instr. 4)	
						of (Ins									(s) (I) (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
ROSENWALD LINDSAY A MD 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

Signatures

/s/ James F. Oliviero, Attorney-in-Fact	06/09/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 24,390 shares of restricted Common Stock will vest on June 5, 2023, subject to Dr. Rosenwald's continued service on the board on such
- (2) Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.